Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 11738 for:    Oral Cancer

Adjuvant ChemoRadiotherapy Prior to Surgery in Stage IVa Oral Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03923998
Recruitment Status : Completed
First Posted : April 23, 2019
Last Update Posted : April 23, 2019
Sponsor:
Collaborators:
Tata Capital Limited
Grant Medical Foundation Ruby hall Clinic
Information provided by (Responsible Party):
Dr. Sanjay Deshmukh, Indrayani Hospital and Cancer Institute

Brief Summary:
Oral cancer is the single largest cancer in males in India. 90-95% cases of oral cancer are Squamous cell carcinomas and many of them present at late stages (T3 and above). Treatment of OSCC includes single modality surgery, radiotherapy, or combinations of these modalities with or without systemic therapy. For unresectable cases, radiotherapy and/or chemotherapy is the treatment modality. Efficacy of neoadjuvant chemoradiotherapy for resectable stage IV tumors (late stage) needs to be evaluated to assess its benefit before surgery.

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of Oral Cavity Drug: Neoadjuvant chemotherapy Radiation: Neoadjuvant radiotherapy Procedure: Resection and reconstruction Early Phase 1

Detailed Description:

This study will assess the benefit of preoperative adjuvant chemoradiotherapy in patients with an Stage IVa oral squamous cell carcinoma (OSCC). The study population will consist of patients who have not been treated previously. Patients satisfying the inclusion-exclusion criteria will be included in the study after obtaining a valid, written and informed consent. After reviewing the histopathological report, the patients will be treated as per the study protocol. The patients will be under regular follow-up with 3 monthly intervals for a period of one year and 6 monthly period in the following years. At each follow-up, patients will be evaluated clinically for evidence of locoregional tumor recurrence. The locoregional recurrence-free survival will be calculated based on the difference between the date of inclusion and the date of biopsy-proven recurrence. We will also record the overall survival, parameters like trismus, osteonecrosis and xerostomia. Quality of life will be assessed at a regular interval of 1 year using the University of Washington Quality of Life Questionnaire (UW-QOL v.4)

Study protocol:

  1. Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
  2. Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
  3. Initial surgery in leg for Prefabrication of fibula - 2 weeks after starting of radiotherapy treatment. Delay is required for planning of implant position in the fibula.
  4. Definitive surgical procedure with reconstruction by prefabricated flap, 6 weeks post radiotherapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessing Efficacy of Neoadjuvant Chemoradiotherapy as a Treatment Plan for Patients With Stage IVa Oral Cancer.
Actual Study Start Date : March 15, 2016
Actual Primary Completion Date : March 15, 2019
Actual Study Completion Date : March 15, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Oral Cancer

Arm Intervention/treatment
Experimental: Neoadjuvant chemoradiotherapy followed by surgery
Preoperative chemotherapy with concurrent radiotherapy followed by definitive surgery
Drug: Neoadjuvant chemotherapy
Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
Other Name: NACT

Radiation: Neoadjuvant radiotherapy
Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
Other Name: NACTRT

Procedure: Resection and reconstruction
Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
Other Name: Mandibulectomy/Maxillectomy and reconstruction by free fibula flap




Primary Outcome Measures :
  1. Objective response rate [ Time Frame: Upto 1 year ]
    This will be deduced from pathological response in terms of complete and partial response. Complete response is defined as no invasive and no in situ residuals present in the surgical specimen. Partial response defined as at least a 30% reduction in the size of the lesion in the surgical specimen.

  2. Disease free survival [ Time Frame: 2 years ]
    Disease-free survival will be calculated as the time interval (months) between primary treatment and the first recurrence (whether local, regional or distant).

  3. Overall Survival [ Time Frame: 2 years ]
    Overall Survival will be calculated as the time interval (months) between primary treatment and death.


Secondary Outcome Measures :
  1. Quality of life assessment [ Time Frame: 2 years ]
    Patient reported quality of life will be assessed at a regular interval of 1 year using the University of Washington Quality of Life Questionnaire (UW-QOL v.4). The minimum score is 0 which is indicative of worse outcome while 100 is the maximum score and indicative of better outcome. Various parameters including chewing, pain, swallowing, saliva, appearance etc. are included in the questionnaire. Average score for each parameter with standard deviation will be reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed stage IVa squamous cell carcinoma of the oral cavity.
  2. Surgically resectable oral squamous carcinoma with invasion of mandible or maxilla.
  3. Newly diagnosed or previously untreated squamous cell carcinoma of the oral cavity.

Exclusion Criteria:

  1. Patients with distant metastases.
  2. Patients with contraindication to radiotherapy.
  3. Patients with vascular disorders or ischemic heart disease. -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03923998


Locations
Layout table for location information
India
Indrayani hospital and cancer institute
Pune, Maharshtra, India, 412105
Sponsors and Collaborators
Indrayani Hospital and Cancer Institute
Tata Capital Limited
Grant Medical Foundation Ruby hall Clinic
Investigators
Layout table for investigator information
Principal Investigator: Sanjay Deshmukh, MS Indrayani Hospital and Cancer Institute

Layout table for additonal information
Responsible Party: Dr. Sanjay Deshmukh, Surgical Oncologist, Indrayani Hospital and Cancer Institute
ClinicalTrials.gov Identifier: NCT03923998     History of Changes
Other Study ID Numbers: OIT415
First Posted: April 23, 2019    Key Record Dates
Last Update Posted: April 23, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual patient data for all primary and secondary outcomes will be made available.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: The data will be made available 4 months post completion of the study.
Access Criteria: The data will be made available on request. Requestors will need to sign a data access agreement to obtain the data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dr. Sanjay Deshmukh, Indrayani Hospital and Cancer Institute:
Oral neoplasms
Mouth neoplasms

Additional relevant MeSH terms:
Layout table for MeSH terms
Mouth Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site
Mouth Diseases
Carcinoma, Squamous Cell
Carcinoma
Stomatognathic Diseases